News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
259,197 Results
Type
Article (13832)
Company Profile (293)
Press Release (245072)
Section
Business (79305)
Career Advice (147)
Deals (13176)
Drug Delivery (31)
Drug Development (50264)
Employer Resources (31)
FDA (5668)
Job Trends (5110)
News (144022)
Policy (10013)
Tag
Academia (901)
Alliances (21440)
Alzheimer's disease (731)
Approvals (5632)
Artificial intelligence (61)
Bankruptcy (97)
Best Places to Work (4468)
Biotechnology (241)
Breast cancer (57)
Cancer (599)
Cardiovascular disease (52)
Career advice (128)
CAR-T (48)
Cell therapy (156)
Clinical research (39605)
Collaboration (205)
Compensation (85)
COVID-19 (998)
C-suite (58)
Cystic fibrosis (61)
Data (641)
Diabetes (65)
Diagnostics (1191)
Earnings (28677)
Events (46597)
Executive appointments (157)
FDA (5917)
Funding (210)
Gene editing (51)
Gene therapy (130)
GLP-1 (292)
Government (1063)
Healthcare (6528)
Infectious disease (1028)
Inflammatory bowel disease (89)
IPO (7169)
Job creations (859)
Job search strategy (124)
Layoffs (182)
Legal (1372)
Lung cancer (101)
Manufacturing (68)
Medical device (2547)
Medtech (2548)
Mergers & acquisitions (6090)
Metabolic disorders (204)
Neuroscience (913)
NextGen Class of 2024 (1997)
Non-profit (842)
Northern California (806)
Obesity (117)
Opinion (90)
Parkinson's disease (55)
Patents (47)
People (24902)
Pharmaceutical (48)
Phase I (13923)
Phase II (18412)
Phase III (11689)
Pipeline (168)
Postmarket research (846)
Preclinical (5883)
Radiopharmaceuticals (203)
Rare diseases (144)
Real estate (1409)
Regulatory (8166)
Research institute (930)
Southern California (748)
Startups (1963)
United States (6786)
Vaccines (154)
Weight loss (74)
Date
Today (118)
Last 7 days (529)
Last 30 days (1925)
Last 365 days (20624)
2024 (17926)
2023 (22412)
2022 (26822)
2021 (27806)
2020 (23357)
2019 (16224)
2018 (11738)
2017 (13745)
2016 (11839)
2015 (14349)
2014 (10392)
2013 (7484)
2012 (7532)
2011 (7614)
2010 (7428)
Location
Africa (146)
Asia (16771)
Australia (2821)
California (1834)
Canada (654)
China (137)
Colorado (70)
Connecticut (72)
Europe (36106)
Florida (198)
Georgia (53)
Illinois (112)
Indiana (53)
Kansas (54)
Maryland (278)
Massachusetts (1534)
Michigan (45)
Minnesota (83)
New Jersey (497)
New York (552)
North Carolina (384)
Northern California (806)
Ohio (73)
Pennsylvania (386)
South America (207)
Southern California (748)
Texas (192)
Washington State (199)
259,197 Results for "rubryc therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
RubrYc Therapeutics Announces Series A2 Preferred Equity Financing, Collaboration, and RTX-003 License with iBio, Inc.
RubrYc Therapeutics, Inc. (“RubrYc”) and iBio, Inc. (“iBio”, NYSEA: IBIO) announced today the closing of RubrYc’s Series A2 Preferred Financing, and concomitant License and Collaboration Agreements directed towards the research, development, and commercialization of epitope-targeted antibody therapeutics.
August 25, 2021
·
4 min read
iBio Acquires RubrYc Therapeutics’ AI Drug Discovery Platform and Pipeline
SAN DIEGO and BRYAN, Texas, Sept. 21, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming® Manufacturing System
November 10, 2022
·
7 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Business
RubrYc Therapeutics Announces a Research Collaboration and License Option Agreement With Zai Labs
RubrYc Therapeutics, Inc., a pre-clinical biotherapeutics company developing epitope selective therapies, today announced that it has entered into a research collaboration and license option agreement with Zai Labs, Inc. for the use of RubrYc’s Meso-scale Engineered Molecules (MEMs) platform, to identify monoclonal antibodies with enhanced biological function for an undisclosed oncology target.
April 13, 2021
·
2 min read
Biotech Bay
RubrYc Therapeutics To Present at AACR Virtual Conference
RubrYc Therapeutics, Inc., a pre-clinical biotherapeutics company developing epitope selective therapies to improve outcomes for cancer and serious autoimmune disease patients, today announced the presentation of discovery and pre-clinical data from their lead program RTX-003, a CD25 targeted monoclonal antibody for selective depletion of regulatory T cells (Tregs) in the tumor microenvironment (TME). A poster ti
June 23, 2020
·
3 min read
Press Releases
NeuroEM Therapeutics(R) Accepted into StartUp Health’s Alzheimer’s Moonshot Community(TM)
September 19, 2024
·
4 min read
Layoffs
Spero Therapeutics to Lay Off 39% of Employees
Following disappointing results for an antibiotic candidate whose development program is now being suspended, Spero Therapeutics is looking to extend its cash runway while it focuses on other assets in its pipeline.
October 30, 2024
·
1 min read
·
Angela Gabriel
Layoffs
Viracta Therapeutics Cuts 42% of Staff as Part of Resource Reprioritization
Following two layoffs in less than three months, Viracta Therapeutics may have around 18 employees left to advance its efforts to bring lead product candidate nana-val to market.
November 7, 2024
·
2 min read
·
Angela Gabriel
Business
RubrYc Therapeutics Announces formation of its Scientific Advisory Board
RubrYc’s SAB will leverage synergistic expertise in structural and computational biology, translational sciences, and market and clinical insights.
December 4, 2019
·
4 min read
Drug Development
RubrYc Therapeutics Appoints Ramesh Baliga, Ph.D. as Chief Science Officer
RubrYc Therapeutics, Inc., a pre-clinical biotherapeutics company developing epitope selective therapies to improve outcomes for cancer and serious autoimmune disease patients, today announced the appointment of Ramesh Baliga, Ph.D., as the Company’s Chief Science Officer.
March 18, 2020
·
3 min read
1 of 25,920
Next